Regulatory & Safety

Rexahn licenses pancreatic cancer drug candidate in China

Rexahn, a clinical stage biopharmaceutical company, will grant China-based BioSense an exclusive license to develop and commercialize its pancreatic cancer treatment, RX-3117, in greater China. BioSense will provide Rexahn an upfront payment and, contingent upon development, regulatory and commercial milestones and achievements, a potential further $226m (€200.22m). At the time Czytaj więcej…